Marla Dubinsky, MD, on Proactive Therapeutic Monitoring
06/17/2020
In this podcast, Marla Dubinsky, MD, discusses her research on assays for measuring drug concentrations and anti-drug antibodies, as well as algorithmic approaches to proactive therapeutic drug monitoring and how they help patients with inflammatory bowel disease achieve and maintain remission. Read the full transcript here.
Additional Resources:
- Dubinsky M, Phan BL, Tse S, Mould DR. 240 Real-world application of an adaptive dosing dashboard reveals accelerated induction dosing of infliximab is necessary in most IBD patients and improves therapeutic outcomes. Gastroenterology. 2020;158(6):S47-S48. doi.org/10.1016/S0016-5085(20)30801-5
- Vermeire S, Dreesen E, Papamichael K, Dubinsky MC. How, when, and for whom should we perform therapeutic drug monitoring? Clin Gastroenterol Hepatol. 2020;18(6):1291-1299. doi.org/10.1016/j.cgh.2019.09.041
- Strik, AS, Berends SE, Mould DR, Dubinsky M. Dashboard driven dosing of infliximab is superior to conventional treatment in inflammatory bowel disease: the precision randomized controlled trial. Gastroenterology. 2019;156(6):S180-S181. doi.org/10.1016/S0016-5085(19)37240-3
Marla Dubinsky, MD, is division chief of pediatric gastroenterology and nutrition and codirector of the Susan and Leonard Feinstein IBD Clinical Center at the Icahn School of Medicine at Mt. Sinai in New York City.
